Severe infusion reactions to infliximab: Aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 1, 2011, Pages 51-58

  Steenholdt, C ^a,c   Svenson, M ^b   Bendtzen, K ^b   Thomsen, O A ^a   Brynskov, J ^a   Ainsworth, M A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Biomonitor A/S   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CETIRIZINE; DRUG ANTIBODY; HYDROCORTISONE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; INFLIXIMAB ANTIBODY; PARACETAMOL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROHN DISEASE; CROSS REACTION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG WITHDRAWAL; ENTERITIS; EPISODIC DRUG INFUSION; FEMALE; HUMAN; IMMUNOGENICITY; INFUSION REACTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 79958095982     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04682.x     Document Type: Article

References (31)

1. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-39. (Pubitemid 47031141)
2. Miehsler W, Novacek G, Wenzl H, et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010; 4: 221-56.
3. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
4. Vermeire S, Van AG, Rutgeerts P,. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009; 23: 101-12.
5. Maggi E, Vultaggio A, Matucci A,. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011; 7: 55-63.
6. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P,. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24. (Pubitemid 36389794)
7. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T,. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-9. (Pubitemid 44955878)
8. Svenson M, Geborek P, Saxne T, Bendtzen K,. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46: 1828-34. (Pubitemid 350168300)
9. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-45.
10. Svenson M, Jacobi HH, Bodtger U, Poulsen LK, Rieneck K, Bendtzen K,. Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. Mol Immunol 2003; 39: 603-12. (Pubitemid 35335839)
11. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA,. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2010; 46: 310-8.
12. Cassinotti A, Travis S,. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-75.
13. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53. (Pubitemid 38834038)
14. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
15. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
16. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8. (Pubitemid 36204954)
17. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP,. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006; 118: 11-9. (Pubitemid 43012041)
18. Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-61.
19. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24. (Pubitemid 36741529)
20. Sampson HA, Mendelson L, Rosen JP,. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327: 380-4.
21. Duburque C, Lelong J, Iacob R, et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006; 24: 851-8.
22. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J,. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009; 44: 774-81.
23. Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H,. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000; 235: 71-80. (Pubitemid 30089785)
24. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97: 1408-14. (Pubitemid 34664785)
25. Crandall WV, Mackner LM,. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75-84. (Pubitemid 36140437)
26. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31. (Pubitemid 38040720)
27. Breynaert C, Ferrante M, Fidder H, et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 2011; 106: 778-85.
28. Margo F, Marques M, Santos CC,. Episodic infliximab treatment induces infusion reactions. Inflamm Bowel Dis 2008; 14: 1608-10.
29. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
30. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009; 29: 286-97.
31. Zabana Y, Domenech E, Manosa M, et al. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010; 31: 553-60.